OXFORD BIOMEDICA ORD 50P news, videos and press releases
For more news please use our advanced search feature.
OXFORD BIOMEDICA ORD 50P - More news...
OXFORD BIOMEDICA ORD 50P - More news...
- Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
- Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
- Oxford Biomedica to host a free webinar showcasing its AAV expertise
- Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
- Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
- Oxford Biomedica completes acquisition of ABL Europe
- Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
- Business Update
- Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
- Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
- Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
- Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
- Oxford Biomedica to host webinar showcasing the TetraVecta™ system
- Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook
- Oxford Biomedica Implements Sapio Sciences' Electronic Laboratory Notebook
- Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
- Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
- Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
- Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
- Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
- Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree
- OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
- Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
- Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
- Oxford Biomedica Preliminary Results
- Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
- Oxford Biomedica announces update to agreement with Sio Gene Therapies
- Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner
-
Oxford Biomedica: Edison Open House Healthcare 2022
- John Dawson to retire from Oxford Biomedica
